Research To Practice | Oncology Videos

Featuring an interview with Dr Toni Choueiri, including the following topics: Case: A woman in her early 70s with a large kidney tumor and multiple pulmonary nodules (0:00) Case: A woman in her early 60s diagnosed with metastatic clear cell renal cell carcinoma (RCC) (12:52) Approach to adjuvant treatment for RCC (16:14) Examining differences between PD-1 and PD-L1 inhibitors (20:09) Management of non-clear cell RCC (24:10) Challenges in identifying patients with RCC who are more likely to benefit from immune checkpoint inhibitors (28:22) Mechanisms of action of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (30:31) Future directions in the care of patients with RCC (36:24) CME information and select publications

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 2: Anti-PD-1 and PD-L1 Monotherapy for NSCLC — Dr Stephen Liu CME information and select publications

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 1: Current Treatment Landscape for Non-Small Cell Lung Cancer (NSCLC) — Dr John Heymach CME information and select publications

Featuring perspectives from Drs John Heymach and Stephen Liu, including the following topics: Introduction (0:00) Current Immunotherapy-Based Strategies for Non-Small Cell Lung Cancer (NSCLC) (9:29) Future Directions in the Management of NSCLC (37:09) CME information and select publications

Featuring perspectives from Dr Lisa Carey, including the following topics: Introduction: Journal Club with Lisa A Carey, MD, ScM (0:00) Case: A woman in her late 70s presents with triple-positive breast cancer and a suspicious mass in the liver — Zanetta S Lamar, MD (8:51) Case: A woman in her mid 40s with ER/PR-negative, HER2-positive metastatic breast cancer with a complete response to paclitaxel/trastuzumab/pertuzumab develops multiple brain metastases 3 months later — Niyati A Nathwani, MD (19:01) Case: A woman in her mid 30s with triple-positive breast cancer develops brain metastases 5 years after primary neoadjuvant treatment — Rahul Gosain, MD (22:23) Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer experiences progressive disease after abemaciclib/ovarian function suppression and an aromatase inhibitor — Laila Agrawal, MD (28:22) Case: A woman in her early 60s with ER/PR-positive, HER2-negative localized breast cancer develops triple-positive metastatic breast cancer — Mamta Choksi, MD (41:16) Case: A woman in her early 50s with 1.2-cm triple-positive breast cancer who underwent mastectomy (surgical specimen HER2-negative) and adjuvant paclitaxel/trastuzumab now presents with HER2-negative localized recurrence — Namrata I Peswani, MD (43:37) Faculty Survey (47:53) Ongoing Trials; Reported Data; Review Articles (55:01) CME information and select publications

Featuring a slide presentation and related discussion from Professor Arndt Vogel, including the following topics: Advances in first-line treatment for patients with advanced hepatocellular carcinoma (HCC) (0:00) Outcomes of Phase III clinical trials evaluating single-agent immunotherapy as initial treatment for advanced HCC (4:19) Immune checkpoint inhibitors as second-line treatment for recurrent HCC (6:03) Combination therapy as initial treatment for advanced HCC (8:05) Sequencing therapies for advanced HCC (13:20) Future directions in caring for patients with advanced HCC (22:43) CME information and select publications

Featuring an interview with Professor Arndt Vogel, including the following topics: Case: A man in his early 40s with hepatitis B virus infection and hepatocellular carcinoma (HCC) with Child-Pugh C, ALBI 3 cirrhosis (0:00) Case: A man in his late 60s with metastatic HCC with Child-Pugh A, ALBI 2 cirrhosis (7:54) Case: A man in his early 70s with rheumatoid arthritis diagnosed with Barcelona Clinic Liver Cancer Stage 2 HCC (10:54) The etiology of HCC and response to immunotherapy (13:20) Evaluating recent first-line Phase III combination trials for unresectable HCC (19:57) Managing treatment-emergent adverse events with combination therapies for advanced HCC (25:47) Potential long-term benefits of immunotherapy-based treatments (29:33) Impact of recent changes in HCC treatment algorithms on the use of local therapy (31:46) Use of neoadjuvant therapy to convert unresectable HCC to resectable disease (37:00) Using tyrosine kinase inhibitors for patients with HCC and comorbidities (44:22) CME information and select publications

Featuring an interview with Dr Eytan Stein, including the following topics: Practical considerations for using venetoclax/HMA (hypomethylating agent) combinations in the management of acute myeloid leukemia (AML) (0:00) Approach to transplant for older patients with AML (10:33) Potential availability of magrolimab and sabatolimab in clinical practice (13:04) ASH 2022 preview: Investigational therapies excluding transplantation and cellular immunotherapies (17:33) Activity, tolerability and future directions with FLT3 and IDH inhibitors in AML (22:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr Eytan Stein, including the following topics: Historical paradigms for treating newly diagnosed acute myeloid leukemia (AML) (0:00) Long-term findings and emerging results with venetoclax-based therapies for newly diagnosed and relapsed/refractory (R/R) AML (1:19) Efficacy and tolerability of oral decitabine/cedazuridine for patients with AML (19:27) Mechanism of action, activity and safety of magrolimab-based therapies for newly diagnosed and R/R disease (23:34) Sabatolimab: Mechanism of action and efficacy in combination with a hypomethylating agent (32:01) Therapeutic targeting of Menin and NPM1 mutations in AML; activity of entospletinib in combination with induction chemotherapy (37:29) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in melanoma. Featuring perspectives from Prof Georgina Long, including the following topics: Neoadjuvant and Adjuvant Therapy for Melanoma (0:00) Update on the Management of Metastatic Melanoma (19:23) CME information and select publications